Loading...
XSTO
BIOSGN
Market cap14mUSD
May 26, Last price  
0.57SEK
1D
2.15%
1Q
57.46%
IPO
-92.19%
Name

Biosergen AB

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.53%
Rev. gr., 5y
%
Revenues
0k
1,314,2894,432,0008,573,000000
Net income
-19m
L-30.50%
-5,420,162-7,222,000-34,558,000-33,913,000-27,037,000-18,791,000
CFO
-17m
L-48.99%
-2,314,424-4,584,000-37,749,000-29,441,000-32,603,000-16,631,000

Profile

Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
URL
https://biosergen.net/
IPO date
Jun 24, 2021
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
456
280
Unusual Expense (Income)
NOPBT
(456)
(280)
NOPBT Margin
Operating Taxes
(135)
Tax Rate
NOPAT
(456)
(145)
Net income
(18,791)
-30.50%
(27,037)
-20.28%
(33,913)
-1.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
65,360
5,297
37,118
BB yield
-52.52%
-13.40%
-67.00%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(50,612)
(1,883)
(29,342)
Cash flow
Cash from operating activities
(16,631)
(32,603)
(29,441)
CAPEX
Cash from investing activities
Cash from financing activities
65,360
5,297
37,118
FCF
233
(689)
(145)
Balance
Cash
50,612
1,883
29,342
Long term investments
Excess cash
50,612
1,883
29,342
Stockholders' equity
1,266
22,815
Invested Capital
49,141
850
(22)
ROIC
686.16%
ROCE
EV
Common stock shares outstanding
234,823
44,927
52,764
Price
0.53
-39.77%
0.88
-16.19%
1.05
-80.63%
Market cap
124,456
214.80%
39,535
-28.64%
55,403
-80.89%
EV
73,844
37,652
26,061
EBITDA
(456)
(280)
EV/EBITDA
Interest
54
Interest/NOPBT